Spencer Bsc Byaruhanga
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Spencer Bsc Byaruhanga has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- A. Sarah Walker
Nuffield Department of Medicine, University of Oxford
2 shared publications - Eva Natukunda
Department of Paediatrics, Joint Clinical Research Centre, Kampala, Uganda
2 shared publications - Katja Doerholt
Medical Research Council Clinical Trials Unit, University College London, London, United Kingdom
2 shared publications Philippa Musoke
Department of Paediatrics and Child Health, College of Health Sciences, Makerere University, Kampala, Uganda
2 shared publications- Victor Musiime
Department of Paediatrics and Child Health, Makerere University Kampala
2 shared publications - Abbas Msc Lugemwa
Joint Clinical Research Centre, Mbarara, Uganda
1 shared publication
Latest Publications
- 24 February 2026
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 45 (9) , 768-775
Body Composition Changes in Children Living With HIV Initiated on Dolutegravir or Protease Inhibitors in the CHAPAS-4 Trial
Background: Few studies have compared body composition changes in children living with HIV receiving integrase inhibitors or boosted protease inhibitors. Methods: Children switching to second-line antiretroviral therapy were randomized to dolutegravir (DTG), darunavir/ritonavir (DRV/r), atazanavir/ritonavir (ATV/r) or lopinavir/ritonavir (LPV/r), and to tenofovir alafenamide (TAF) or standard of care (abacavir or zidovudine) using a factorial design. Body composition was measured using bioelectric impedance analysis over 96 weeks. Associations between baseline characteristics and changes in fat mass, fat-free mass, muscle mass and body fat percentage were estimated using robust regression with multivariable fractional polynomial selection (exit P = 0.05). Results: Eight hundred forty-one participants were included in the analysis. Females compared with males had greater fat accrual (+4.66% body fat, +1.32 kg fat mass; both P < 0.001). Compared with LPV/r, ATV/r and DTG exposures were associated with higher fat-free mass [+0.85 kg (95% confidence interval: 0.43–1.27) and +0.79 kg (0.37–1.21) respectively] and muscle mass [+0.82 kg (0.41–1.23) and +0.82 kg (0.42–1.22), respectively] (all P < 0.001). TAF and DRV/r exposures were associated with higher fat mass [+0.32 kg (0.12–0.52) P = 0.002; +0.33 kg (0.04–0.61) P = 0.025, respectively]. Prior nevirapine exposure was also associated with greater fat accrual [+0.36 kg (0.13–0.58) vs. efavirenz, P = 0.002]. Baseline CD4 and viral load, time on first-line antiretroviral therapy, and site were also associated with composition changes. Conclusions: DTG and ATV/r were associated with greater gains in fat-free mass and muscle mass than LPV/r, while DRV/r, TAF and prior nevirapine exposure were associated with fat mass accrual. Fat gain may initially reflect return to health but sustained increases may have metabolic implications. These findings suggest the need to monitor fat compartments with long-term exposure.
- 24 February 2026
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 45 (9) , 768-775
Body Composition Changes in Children Living With HIV Initiated on Dolutegravir or Protease Inhibitors in the CHAPAS-4 Trial
Background: Few studies have compared body composition changes in children living with HIV receiving integrase inhibitors or boosted protease inhibitors. Methods: Children switching to second-line antiretroviral therapy were randomized to dolutegravir (DTG), darunavir/ritonavir (DRV/r), atazanavir/ritonavir (ATV/r) or lopinavir/ritonavir (LPV/r), and to tenofovir alafenamide (TAF) or standard of care (abacavir or zidovudine) using a factorial design. Body composition was measured using bioelectric impedance analysis over 96 weeks. Associations between baseline characteristics and changes in fat mass, fat-free mass, muscle mass and body fat percentage were estimated using robust regression with multivariable fractional polynomial selection (exit P = 0.05). Results: Eight hundred forty-one participants were included in the analysis. Females compared with males had greater fat accrual (+4.66% body fat, +1.32 kg fat mass; both P < 0.001). Compared with LPV/r, ATV/r and DTG exposures were associated with higher fat-free mass [+0.85 kg (95% confidence interval: 0.43–1.27) and +0.79 kg (0.37–1.21) respectively] and muscle mass [+0.82 kg (0.41–1.23) and +0.82 kg (0.42–1.22), respectively] (all P < 0.001). TAF and DRV/r exposures were associated with higher fat mass [+0.32 kg (0.12–0.52) P = 0.002; +0.33 kg (0.04–0.61) P = 0.025, respectively]. Prior nevirapine exposure was also associated with greater fat accrual [+0.36 kg (0.13–0.58) vs. efavirenz, P = 0.002]. Baseline CD4 and viral load, time on first-line antiretroviral therapy, and site were also associated with composition changes. Conclusions: DTG and ATV/r were associated with greater gains in fat-free mass and muscle mass than LPV/r, while DRV/r, TAF and prior nevirapine exposure were associated with fat mass accrual. Fat gain may initially reflect return to health but sustained increases may have metabolic implications. These findings suggest the need to monitor fat compartments with long-term exposure.
- Open Access
- 17 February 2026
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 6 (2) , e0005979
Longitudinal changes in bone mineral density among children living with HIV over 96 weeks following switch to second-line antiretroviral therapy in Uganda
Long-term impact of antiretroviral therapy (ART) on bone health in children living with HIV (CLWH) remains uncertain. We aimed to determine associations of change in bone mineral density (BMD) among CLWH in Uganda in a 2-year prospective sub-study in the CHAPAS-4 randomized trial (ISRCTN22964075). CLWH aged 3–15 years switched to second-line ART including tenofovir alafenamide fumarate-emtricitabine (TAF/FTC) or standard-of-care (SOC) (abacavir (ABC) or zidovudine (ZDV) with dolutegravir (DTG), atazanavir/ritonavir (ATV/r), darunavir/ritonavir (DRV/r) or lopinavir/ritonavir (LPV/r). BMD was assessed by dual-energy X-ray absorptiometry (DXA) at baseline, weeks 48 and 96 and bone turnover markers measured at baseline, week 24, 48, and 96. Robust regression analysis determined associations of BMD and bone turnover markers through week 96. Of 196 participants,167 contributed BMD measurements. Median (IQR) age was 9.9(7.0,12.3) years, 47% male, median (IQR) CD4 T-cell count 797(537,1140) cells/µl and mean (SD) viral load (log 10 copies/ml) 4.3(0.8). Change in Procollagen type I N-terminal propeptide (PINP), C-terminal telopeptide of type I collagen (CTX) and height-adjusted (HA) BMD were similar between TAF/FTC and SOC. Greater declines in total-body-less-head (TBLH) BMD were associated with higher baseline TBLH (HA) BMD (Coef. -0.30,95% CI: -0.46, -0.15], p < 0.001) and first-line nevirapine (NVP) exposure (-0.25,95% CI: -0.43, -0.06, p = 0.009). Smaller TBLH HA BMD declines were associated with higher baseline fat-mass (0.06, 95% CI:0.01, 0.11, p = 0.021), higher lumbar spine (LS) HA BMD (0.17, 95% CI:0.03, 0.31, p = 0.015), DRV/r (0.46, p < 0.001,95% CI:0.21,0.71), DTG (0.26, p = 0.041,95% CI:0.01,0.51) or ATV/r (0.28, p = 0.026, 95% CI: 0.03, 0.52) use compared with LPV/r. Smaller declines in TBLH BMD were associated with higher baseline fat mass, higher LS HA BMD, and use of DRV/r, DTG, or ATV/r compared with LPV/r. These findings emphasize the importance of ART selection and body composition in supporting bone health among CLWH.
- 17 February 2026
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 6 (2) , e0005979
Open AccessLongitudinal changes in bone mineral density among children living with HIV over 96 weeks following switch to second-line antiretroviral therapy in Uganda
Long-term impact of antiretroviral therapy (ART) on bone health in children living with HIV (CLWH) remains uncertain. We aimed to determine associations of change in bone mineral density (BMD) among CLWH in Uganda in a 2-year prospective sub-study in the CHAPAS-4 randomized trial (ISRCTN22964075). CLWH aged 3–15 years switched to second-line ART including tenofovir alafenamide fumarate-emtricitabine (TAF/FTC) or standard-of-care (SOC) (abacavir (ABC) or zidovudine (ZDV) with dolutegravir (DTG), atazanavir/ritonavir (ATV/r), darunavir/ritonavir (DRV/r) or lopinavir/ritonavir (LPV/r). BMD was assessed by dual-energy X-ray absorptiometry (DXA) at baseline, weeks 48 and 96 and bone turnover markers measured at baseline, week 24, 48, and 96. Robust regression analysis determined associations of BMD and bone turnover markers through week 96. Of 196 participants,167 contributed BMD measurements. Median (IQR) age was 9.9(7.0,12.3) years, 47% male, median (IQR) CD4 T-cell count 797(537,1140) cells/µl and mean (SD) viral load (log 10 copies/ml) 4.3(0.8). Change in Procollagen type I N-terminal propeptide (PINP), C-terminal telopeptide of type I collagen (CTX) and height-adjusted (HA) BMD were similar between TAF/FTC and SOC. Greater declines in total-body-less-head (TBLH) BMD were associated with higher baseline TBLH (HA) BMD (Coef. -0.30,95% CI: -0.46, -0.15], p < 0.001) and first-line nevirapine (NVP) exposure (-0.25,95% CI: -0.43, -0.06, p = 0.009). Smaller TBLH HA BMD declines were associated with higher baseline fat-mass (0.06, 95% CI:0.01, 0.11, p = 0.021), higher lumbar spine (LS) HA BMD (0.17, 95% CI:0.03, 0.31, p = 0.015), DRV/r (0.46, p < 0.001,95% CI:0.21,0.71), DTG (0.26, p = 0.041,95% CI:0.01,0.51) or ATV/r (0.28, p = 0.026, 95% CI: 0.03, 0.52) use compared with LPV/r. Smaller declines in TBLH BMD were associated with higher baseline fat mass, higher LS HA BMD, and use of DRV/r, DTG, or ATV/r compared with LPV/r. These findings emphasize the importance of ART selection and body composition in supporting bone health among CLWH.